Cargando…
Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and ultimately fatal disease for which only palliative treatments existed until recently. Between 2011 and 2015, two new drugs, pirfenidone and nintedanib, were approved in the US and Europe for the treatment of IPF, providing hope for patients....
Autores principales: | Audibert, Céline, Livoti, Christine, Caze, Alexis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935841/ https://www.ncbi.nlm.nih.gov/pubmed/29736460 http://dx.doi.org/10.1016/j.conctc.2016.04.008 |
Ejemplares similares
-
Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis
por: Skandamis, Aristeidis, et al.
Publicado: (2019) -
Recent Advances in Idiopathic Pulmonary Fibrosis
por: Park, Sanghoon, et al.
Publicado: (2013) -
Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022) -
The use of mechanistic evidence in drug approval
por: Aronson, Jeffrey K., et al.
Publicado: (2018) -
Physician characteristics associated with treatment initiation
patterns in idiopathic pulmonary fibrosis
por: LaCamera, Peter P, et al.
Publicado: (2019)